Adenovirus-based prime-boost immunization for rapid vaccination against anthrax (Q40197179)

18 September 2017

Adenovirus-based prime-boost immunization for rapid vaccination against anthrax (English)

1 reference

18 September 2017

0 references

1 reference

Michael J McConnell

1

1 reference

PubMed ID

17164792

18 September 2017

Philip C Hanna

series ordinal

2

1 reference

PubMed ID

17164792

18 September 2017

Michael J Imperiale

series ordinal

3

1 reference

18 September 2017

1 January 2007

1 reference

18 September 2017

1 reference

18 September 2017

15

1 reference

18 September 2017

1

1 reference

18 September 2017

203-210

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

18 September 2017

1 reference

7 January 2021

The roles of anthrax toxin in pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

In vitro correlate of immunity in a rabbit model of inhalational anthrax

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Search for correlates of protective immunity conferred by anthrax vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Recent advances in the development of an improved, human anthrax vaccine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Anthrax vaccine: short-term safety experience in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Jump-starting the immune system: prime-boosting comes of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Induction of immunoglobulin synthesis by CD4+ T cell clones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Biology of E1-deleted adenovirus vectors in nonhuman primate muscle.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Crystal structure of the anthrax toxin protective antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

N-fragment of edema factor as a candidate antigen for immunization against anthrax

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Requirement of the adenovirus IVa2 protein for virus assembly

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Characterization of a permissive epitope insertion site in adenovirus hexon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300034

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300034

1 reference

18 September 2017

1 reference

PubMed ID

17164792